[WEBINAR] Development strategies to keep pace with increasing stereochemical complexity of drug candidates
The percentage of marketed drugs with chiral centers has been growing steadily year-on-year for the past 3 decades. In 2022, 68% of the small molecule drugs approved by FDA had chiral centers, the majority of which had multiple chiral centers.
This trend towards complexity will continue, presenting challenges from a process development and scale-up perspective.
In our webinar, 'Development strategies to keep pace with increasing stereochemical complexity of drug candidates', you will learn how experts leverage the power of PAT, modelling, and other cutting-edge techniques which can be applied to key unit operations (e.g. crystallization, isolation etc.) of enantiomers and diastereomers of varying stereochemical complexity.
This presentation discusses the use of novel techniques and leverage case studies to review:
The importance of integrating a chemical engineering perspective into your synthetic strategy
The utility of PAT in chiral process development
How using ternary phase diagrams with your chiral crystallizations can save time and money